Cogstate Secures $25.4 Million in Q3 2026 Sales Contracts, FY26 Revenue Under Contract Hits $56 Million

Quarterly Sales Contract Growth

Cogstate Ltd (ASX:CGS), a specialist in Central Nervous System (CNS) clinical trial endpoint data and digital cognitive assessments, has reported strong sales contract execution for the quarter ended 31 March 2026 (3Q26). The company secured $25.4 million in new sales contracts during the quarter, bringing the total value of contracts executed over the first nine months of FY26 to $67.1 million. This represents a notable increase compared to the corresponding periods in FY25 and FY24, reflecting sustained demand for Cogstate's technology and services in CNS clinical research.

Revenue Backlog and Contracted Revenue

The company’s contracted revenue backlog has expanded in line with the increased contract execution. Contracted revenue for the June 2026 half-year (2H26), which includes revenue recognised during 3Q26, rose to $29.1 million from $21.7 million at 31 December 2025. This brings the total contracted revenue for the full FY26 financial year, including the $26.9 million recognised in the first half, to $56.0 million. This figure exceeds the total revenue recorded in FY25, which was $53.1 million.

Looking further ahead, contracted revenue for the next financial year (FY27) has also increased, reaching $35.6 million as at 31 March 2026, up from $27.0 million at the end of 2025. These figures indicate a growing revenue pipeline for Cogstate, underpinned by ongoing contract wins in the clinical trials segment.

Business Context and Market Position

Cogstate specialises in providing fit-for-purpose data quality programs, advanced analytics, and digital cognitive testing to pharmaceutical and biotechnology companies conducting CNS clinical trials. The company’s services help determine the cognitive impact of investigational compounds on patient populations, supporting drug development decisions. The length and complexity of clinical trials vary, influencing contract values and revenue recognition timing.

Cogstate’s recent update follows a series of positive financial results, including a 12% revenue growth reported in the half-year ended December 2025, driven by expanding clinical trial contracts and a rising contracted revenue backlog. This momentum was detailed in a prior update highlighting the company’s increasing contracted future Clinical Trials revenue and solid earnings performance, which can be reviewed in more detail in the company’s solid 12% revenue growth and expanding clinical trial contracts update.

Forward-Looking Considerations

While the company’s contract execution and revenue backlog growth are positive indicators, Cogstate’s announcement includes standard forward-looking statements disclaimers. Revenue recognition depends on milestone achievements over the life of clinical trial contracts, which can span several years. Factors such as contract signing timing and trial enrolment rates, which are outside Cogstate’s control, may influence future financial performance. Investors should consider these uncertainties when assessing the company’s outlook.